Dr. John Cullity is Managing Director at BioSynergy Partners, a New York and Melbourne based advisory spun out of Torreya – the renowned life sciences investment bank. He additionally sits on the Boards of several life sciences companies as Chairman of Race Oncology (listed on the ASX), Managing Director at NanoRetinal and Director of HaemaLogiX.

At Torreya, Dr. Cullity provided strategic advisory on Mergers & Acquisitions, Partnering and Financing to life-science companies worldwide. Prior to joining Torreya, he was a senior member of the Business Development team at Sanofi Pharmaceuticals, where he led buy-side transactions in oncology and diabetes. Earlier in his career, Dr. Cullity was Head of Strategic Pricing & Reimbursement at Sanofi, Director of Health Economics at Schering-Plough, and Consultant at A.T. Kearney. He has also worked at The World Bank and the World Health Organization.

Dr. Cullity graduated in Medicine and sub-specialised in haematology-oncology at QE II Medical Centre in Perth. He holds a Bachelor of Medicine, Bachelor of Surgery from The University of Western Australia; Membership in the Royal College of Physicians; Masters in Health Economics from London School of Economics & Political Science, and MBA from The Wharton School, University of Pennsylvania.